BR112019016672A8 - Método para gerar progenitores de células t - Google Patents

Método para gerar progenitores de células t

Info

Publication number
BR112019016672A8
BR112019016672A8 BR112019016672A BR112019016672A BR112019016672A8 BR 112019016672 A8 BR112019016672 A8 BR 112019016672A8 BR 112019016672 A BR112019016672 A BR 112019016672A BR 112019016672 A BR112019016672 A BR 112019016672A BR 112019016672 A8 BR112019016672 A8 BR 112019016672A8
Authority
BR
Brazil
Prior art keywords
cell progenitors
generate
stemregenin
dioxin
cultivating
Prior art date
Application number
BR112019016672A
Other languages
English (en)
Other versions
BR112019016672A2 (pt
Inventor
Andre Isabelle
CAVAZZANA Marina
Ma Kuiying
Tchen John
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Univ Paris Descartes
Inst Nat Sante Rech Med
Univ Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Univ Paris Descartes, Inst Nat Sante Rech Med, Univ Paris filed Critical Hopitaux Paris Assist Publique
Publication of BR112019016672A2 publication Critical patent/BR112019016672A2/pt
Publication of BR112019016672A8 publication Critical patent/BR112019016672A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A invenção refere-se a um método in vitro para gerar os progenitores de células T, compreendendo a etapa de cultivar células CD34+ em meio contendo TNF-alfa e/ou um antagonista do receptor de hidrocarboneto de Aril/Dioxina, em particular StemRegenin 1 (SR1), na presença de um ligante de Notch e, opcionalmente, um fragmento de fibronectina.
BR112019016672A 2017-02-13 2018-02-12 Método para gerar progenitores de células t BR112019016672A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Publications (2)

Publication Number Publication Date
BR112019016672A2 BR112019016672A2 (pt) 2020-04-14
BR112019016672A8 true BR112019016672A8 (pt) 2022-11-08

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019016672A BR112019016672A8 (pt) 2017-02-13 2018-02-12 Método para gerar progenitores de células t

Country Status (15)

Country Link
US (5) US20200046767A1 (pt)
EP (2) EP4067482A1 (pt)
JP (2) JP7164798B2 (pt)
CN (1) CN110506110A (pt)
AU (1) AU2018217404B2 (pt)
BR (1) BR112019016672A8 (pt)
CA (1) CA3053294A1 (pt)
DK (1) DK3580330T3 (pt)
ES (1) ES2931530T3 (pt)
HU (1) HUE060548T2 (pt)
IL (1) IL268641A (pt)
MA (1) MA47541A (pt)
PL (1) PL3580330T3 (pt)
PT (1) PT3580330T (pt)
WO (1) WO2018146297A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506110A (zh) * 2017-02-13 2019-11-26 巴黎公共救济院 产生t细胞祖细胞的方法
CA3077344A1 (en) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
EP3847243A1 (en) * 2018-09-07 2021-07-14 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
EP4058562A4 (en) * 2019-11-14 2023-12-20 Zandstra, Peter William MEDIA FORMULATIONS AND METHODS FOR PRODUCING PRECURSOR CELLS
TW202204609A (zh) * 2020-03-31 2022-02-01 國立大學法人京都大學 Ｔ前驅細胞的製造方法
WO2022248354A1 (en) * 2021-05-25 2022-12-01 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
WO2023079082A1 (en) 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
RU2535966C2 (ru) 2008-09-12 2014-12-20 Криопрашис Криобиоложия Лтда. Клеточная терапия ишемической ткани
EP2352816B1 (en) 2008-11-07 2015-06-24 Sunnybrook Health Sciences Centre Human progenitor t-cells
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
CA2795627C (en) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2014110353A1 (en) 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
AU2014296059B2 (en) 2013-08-02 2020-12-10 The Regents Of The University Of California Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
KR20160145162A (ko) * 2014-04-24 2016-12-19 밀테니 비오텍 게앰베하 유전적으로 변형된 t 세포의 자동화 생성 방법
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
US11555207B2 (en) 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
CA3019845A1 (en) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
CN110506110A (zh) * 2017-02-13 2019-11-26 巴黎公共救济院 产生t细胞祖细胞的方法

Also Published As

Publication number Publication date
ES2931530T3 (es) 2022-12-30
BR112019016672A2 (pt) 2020-04-14
JP2020513844A (ja) 2020-05-21
AU2018217404B2 (en) 2024-03-28
CN110506110A (zh) 2019-11-26
PT3580330T (pt) 2022-12-06
MA47541A (fr) 2019-12-18
DK3580330T3 (da) 2022-12-05
US20230293586A1 (en) 2023-09-21
EP3580330A1 (en) 2019-12-18
US11426430B2 (en) 2022-08-30
CA3053294A1 (en) 2018-08-16
AU2018217404A1 (en) 2019-09-05
US20210169935A1 (en) 2021-06-10
KR20190117550A (ko) 2019-10-16
US20200390817A1 (en) 2020-12-17
JP7164798B2 (ja) 2022-11-02
US11638723B2 (en) 2023-05-02
US20200046767A1 (en) 2020-02-13
US11642376B2 (en) 2023-05-09
AU2018217404A2 (en) 2019-09-19
JP2022185024A (ja) 2022-12-13
US20210169934A1 (en) 2021-06-10
PL3580330T3 (pl) 2023-01-16
RU2019125600A3 (pt) 2021-11-03
HUE060548T2 (hu) 2023-03-28
RU2019125600A (ru) 2021-03-15
IL268641A (en) 2019-10-31
EP3580330B1 (en) 2022-08-31
WO2018146297A1 (en) 2018-08-16
EP4067482A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
BR112019016672A8 (pt) Método para gerar progenitores de células t
NZ765695A (en) Immune cell organoid co-cultures
PH12016502171A1 (en) Apparatus and method for interference mitigation utilizing thin control
CL2016002010A1 (es) Métodos y sistemas para generar mapas colaborativos compartidos
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
MY189778A (en) Method for producing retinal pigment epithelial cells
MX2021006400A (es) Celulas t de memoria central para terapia adoptiva de celulas t.
AU2018397910A1 (en) Nucleic acid-containing lipid nano-particle and use thereof
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
BR112016029871A2 (pt) sistemas e métodos para restrição de parâmetros de formato de representação para um conjunto de parâmetros
MX2016001986A (es) Metodo para preparar rebaudiosido m mediante el uso de un metodo con enzima.
GB2572293A (en) Reactivity mapping
EP3995142A3 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2021008627A (es) Medio de cultivo celular libre de suero.
WO2017100403A8 (en) Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using
CY1122612T1 (el) Μεθοδος
GB2525693A (en) Methods and systems for transmitting and receiving data through tunnel groups
MX2015005627A (es) Sistemas y metodos para conversion de profundidad de datos sismicos 3d utlizando redes neuronales artificiales.
EA201591926A1 (ru) Способ многоцветной проточной цитометрии для идентификации популяции клеток, в частности мезенхимальных стволовых клеток
CL2017001227A1 (es) Ganado lechero híbrido y sistemas para maximizar la ventaja híbrida.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
EP3433971A4 (en) METHODS, SYSTEMS AND SUPPORT FOR USING DYNAMIC PUBLIC KEY INFRASTRUCTURE FOR SENDING AND RECEIVING ENCRYPTED MESSAGES
MX2021007433A (es) Metodos de cultivo de una celula de mamifero.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE PARIS CITE (FR)